Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Retension Pharmaceuticals Inc. market cap is $93.48M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Retension Pharmaceuticals Inc. 52 week high is $18.64 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Retension Pharmaceuticals Inc. 52 week low is $9.23 as of November 22, 2026.
Retension Pharmaceuticals Inc. stock price today is $10.51.
Retension Pharmaceuticals Inc. stock price yesterday was $13.01.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Retension Pharmaceuticals Inc. P/B ratio is -4.5239.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Retension Pharmaceuticals Inc. 50-day moving average is $12.61.